timothy sykes logo
ELVN Stock Jumps As FDA-Cleared Path Fuels Phase 3 Push Thumbnail
G Google News

ELVN Stock Jumps As FDA-Cleared Path Fuels Phase 3 Push

MATT MONACO•UPDATED JUN. 12, 2026, 5:04 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Enliven Therapeutics Inc. stocks have been trading up by 11.62 percent after promising cancer therapy trial results boosted investor optimism.

Key Takeaways

  • Positive updated Phase 1 ENABLE data for ELVN-001 in heavily pretreated CML patients showed strong molecular responses, solid safety, and FDA alignment on an 80 mg dose and pivotal ENABLE-2 Phase 3 design starting 2H 2026.
  • After the data drop, Enliven Therapeutics shares spiked roughly 15% to about $42.50, with ELVN lately trading near $42.48, signaling aggressive momentum trading around the catalyst.
  • Stifel launched coverage on ELVN with a Buy rating and $60 target, calling ELVN-001 well positioned in CML as a complementary option to allosteric drugs like Scemblix.
  • Mizuho lifted its ELVN price target to $62 from $45, kept an Outperform rating, and highlighted a Buy-heavy Street consensus near $58.67–$58.80.
  • Enliven Therapeutics priced an upsized offering of about 8.93M shares and 1.73M pre-funded warrants near $37.50, seeking roughly $400M in gross proceeds plus an underwriters’ option.

Candlestick Chart

Live Update At 17:03:48 EDT: On Friday, June 12, 2026 Enliven Therapeutics Inc. stock [NASDAQ: ELVN] is trending up by 11.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ELVN has been trading like a classic biotech breakout. Over the past few weeks, Enliven Therapeutics shares mostly chopped in the low-to-mid $30s and low $40s, then ripped higher after the new ELVN-001 data. On 2026/06/11, the stock closed at $40.36, and the very next day it opened near $39.77 and pushed as high as $47.36 before finishing at $46.13. That’s real range, and traders love range.

Intraday, ELVN’s 5‑minute chart shows a strong trend day. After a morning shakeout around $40–$42, buyers stepped in and drove a steady staircase higher into the close, with the stock holding above $45 most of the afternoon. That tells traders dip-buyers controlled the tape, not short sellers.

More Breaking News

Fundamentally, Enliven Therapeutics is still a development-stage name. Q1 2026 numbers show no revenue and a net loss of about $23.6M, driven mainly by roughly $20.7M in research spend. But the balance sheet is thick: about $452.4M in cash and short-term investments, virtually no debt, and a massive current ratio above 40. For ELVN traders, that means dilution risk is being addressed up front and the company appears funded to drive ELVN-001 through pivotal work, which is critical when you’re trading a biotech story rather than earnings.

Why Traders Are Watching ELVN Now

ELVN has moved squarely onto momentum traders’ screens because the story just tightened up: data, FDA alignment, Phase 3 path, and cash all arrived in a cluster. Enliven Therapeutics reported updated Phase 1 ENABLE results for ELVN-001 in heavily pretreated chronic myeloid leukemia patients. The drug showed strong major molecular response rates and a clean safety look, even in a tough population. That’s not just “interesting science.” For traders, it’s the fuel behind the tape.

The big kicker is regulatory clarity. Enliven Therapeutics secured FDA alignment on an 80 mg once-daily dose, target population, and core design features for the pivotal ENABLE-2 Phase 3 trial, expected to start in the second half of 2026. When the FDA signs off this early, it removes a chunk of uncertainty. That’s why ELVN ripped premarket and then squeezed intraday as shorts got caught leaning the wrong way.

Wall Street is leaning in too. Stifel initiated ELVN with a Buy and a $60 target, arguing ELVN-001 can fit alongside allosteric CML drugs like Scemblix rather than fight them head-on. Mizuho boosted its target to $62 and reiterated Outperform, while data from FactSet show a Buy-heavy consensus and average targets around the high-$50s. Taken together, the Street is modeling meaningful upside from current ELVN levels if the Phase 3 program executes.

At the same time, management used the pop to price an upsized offering around $37.50, targeting about $400M in gross proceeds plus an underwriters’ option. That’s classic biotech playbook: raise when sentiment is strongest to fund expensive late-stage trials. It can cap near-term spikes, but it also reduces financing overhang, which matters for swing traders eyeing ELVN multi-month moves.

Conclusion

For active traders, ELVN is now a real case study in how clinical catalysts drive price action. Enliven Therapeutics delivered updated Phase 1 data that support a clear, FDA-vetted path into a pivotal ENABLE-2 Phase 3 trial for ELVN-001. The stock responded with a surge from the high $30s into the mid‑$40s, backed by heavy volume and an intraday trend that never really broke. That’s the kind of behavior momentum traders track closely.

At the same time, ELVN is still a high‑risk biotech name. The company is losing money by design as it spends on research, and the upsized offering brings dilution even as it shores up the balance sheet. Analyst targets in the high‑$50s to low‑$60s show how bullish the Street is on ELVN-001, but the real verdict will come from the Phase 3 data, not from price targets or message-board hype.

For traders studying this setup, the playbook is straightforward: track every data update, watch how ELVN trades around conferences like the 2026 EHA Congress, and respect both the upside and the downside. As Tim Sykes likes to remind his students, “The market doesn’t care about your opinion, it cares about catalysts and price action.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. With ELVN, those catalysts are now front and center, and the price action is telling you the whole trading community is paying attention.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading ELVN

Millionaire's
POV on ELVN

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”